## Novo Nordisk Chairman Faces Investor Ire at First Annual Meeting After Boardroom Coup
Novo Nordisk Chairman Lars Rebien Sorensen is bracing for a grilling from investors at the company's first annual meeting since his boardroom coup. The meeting, scheduled for Thursday, comes after Sorensen and new CEO Mike Doustdar have had only a few months to execute their promised transformation of the pharmaceutical giant into a more aggressive and fast-moving entity. However, their early tenure has been marked by notable stumbles that have drawn sharp investor scrutiny.

Investors are pointing to two specific missteps that have undermined confidence in the new leadership's strategy. First, Novo Nordisk failed in a high-stakes attempt last fall to acquire an obesity-focused startup from rival Pfizer, a move seen as critical for bolstering its core metabolic disease portfolio. Second, the company surprised the market earlier this year with an unexpected strategic announcement, the details of which have further fueled concerns about its direction and competitive agility.

The pressure on Sorensen and Doustdar is intensifying as they attempt to steer Novo Nordisk through a period of intense competition, particularly in the lucrative obesity drug market. The investor discontent signals that the boardroom changes have not yet translated into smooth execution or restored full market confidence. The outcome of this annual meeting will serve as a critical barometer for the leadership's ability to manage shareholder relations and deliver on its promised corporate overhaul.
---
- **Source**: STAT News
- **Sector**: The Vault
- **Tags**: pharmaceuticals, corporate governance, investor relations, obesity drugs, boardroom coup
- **Credibility**: unverified
- **Published**: 2026-03-26 14:26:48
- **ID**: 35589
- **URL**: https://whisperx.ai/en/intel/35589